Screening of Stem Genes Regulated by H3K9me2 in Tumor Stem Cells

Abstract

Abstract: In order to analyze and compare the modification differences of the methyltransferase G9a and histone（H3K9me2）between in glioma stem cells and non-stem cells，the related genes maintaining the stem of glioma stem cells were screened. By using G9a inhibitor to facilitate U87 cells into spheres，and G9a overexpression to promote the cell differentiation，the sphered glioma stem cells and monolayer non-stem cells were cultured，and there were significant differences in CD133 expression between the two cell models. Then we used H3K9me2 antibody to compare the differences of H3K9me2 modification between glioma stem cells and non-stem cells via ChIP-seq assay. Genes in the range of TSS ± 2 000 bp among the genes with differences were selected for GO analysis. Moreover，10 transcription factors were randomly selected to confirm the expression level by QPCR，and the result of which was almost consistent with that by ChIP-seq assay.

Key words: ChIP-seq, G9a, H3K9me2, Bix01294, U87 cell line

CLC Number:

10.13560/j.cnki.biotech.bull.1985.2016.12.030

TAO Hong,ZHANG Shao-ping,ZHANG Lin-na,ZHANG Man,HU Qi-kuan,. Screening of Stem Genes Regulated by H3K9me2 in Tumor Stem Cells[J]. Biotechnology Bulletin, 2016, 32(12): 195-202.

References

[1] Li YF, Xiao B, Tu SF, et al. Cultivation and identification of colon cancer stem cell-derived spheres from the Colo205 cell line[J] . Braz J Med Biol Res, 2012, 45（3）：197-204.
[2] Nakanishi Y, Seno H, Fukuoka A, et al. Dclk1 distinguishes between tumor and normal stem cells in the intestine[J] . Nat Genet, 2013, 45（1）：98-103.
[3] Chen J, Li YJ, Yu TS, et al. A restricted cell population propagates glioblastoma growth after chemotherapy[J] . Nature, 2012, 488（7412）：522-526.
[4] Machado HL, Kittrell FS, Edwards D, et al. Separation by cell size enriches for mammary stem cell repopulation activity[J] . Stem Cells Transl Med, 2013, 2（3）：199-203.
[5] Driessens G, Beck B, Caauwe A, et al. Defining the mode of tumour growth by clonal analysis[J] . Nature, 2012, 488（7412）：527-530.
[6] Hinohara K, Kobayashi S, Kanauchi H, et al. ErbB receptor tyrosine kinase/NF-κB signaling controls mammosphere formation in human breast cancer[J] . Proc Natl Acad Sci USA, 2012, 109（17）：6584-6589.
[7] Liao WT, Ye YP, Deng YJ, et al. Metastatic cancer stem cells：from the concept to therapeutics[J] . Am J Stem Cells, 2014, 3（2）：46-62.
[8] Sharma S, Kelly TK, Jones PA. Epigenetics in cancer[J] . Carcinogenesis, 2010, 31（1）：27-36.
[9] Wen B, Wu H, Shinkai Y, et al. Large histone H3 lysine 9 dimethylated chromatin blocks distinguish differentiated from embryonic stem cells[J] . Nat Genet, 2009, 41（2）：246-250.
[10] Zhang J, Gao Q, Li P, et al. S phase-dependent interaction with DNMT1 dictates the role of UHRF1 but not UHRF2 in DNA methylation maintenance[J] . Cell Res, 2011, 21（12）：1723-1739.
[11] Black JC, Van Rechem C, Whetstine JR. Histone lysine methylation dynamics：establishment, regulation and biological impact[J] . Mol cell, 2012, 48（4）：491-507.
[12] Mosammaparast N, Shi Y. Reversal of histone methylation-bioche-mical and molecular mechanisms of histone demethylases[J] . Annu Rev Biochem, 2010, 79（7）：155-179.
[13] Tao H, Li H, Su Y, et al. Histone methyltransferase G9a and H3K9 dimethylation inhibit the self-renewal of glioma cancer stem cells[J] . Mol Cell Biochem, 2014, 394（1-2）：23-30.
[14] Sánchez Alvarado A, Yamanaka S. Rethinking differentiation：stem cells, regeneration and plasticity[J] . Cell, 2014, 157（1）：110-119.
[15] Kreso A, Dick JE. Evolution of the cancer stem cell model[J] . Cell Stem Cell, 2014, 14（3）：275-291.
[16] Park TS, Donnenberg VS, Donnenberg AD, et al. Dynamic interactions between cancer stem cells and their stromal partners[J] . Current Pathobiology Reports, 2014, 1（2）：41-52.
[17] Islam F, Qiao B, Smith RA, et al. Cancer stem cell：fundamental experimental pathological concepts and updates[J] . Exp Mol Pathol, 2015, 98（2）：184-191.
[18] Hanahan D, Weinberg RA. Hallmarks of cancer：the next generation[J] . Cell, 2011, 144（5）：646-674.
[19] Dawson MA, Kouzarides T. Cancer epigenetics：from mechanism to therapy[J] . Cell, 2012, 150（1）：12-27.
[20] Simon C, Chagraoui J, Krosl J, et al. A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia[J] . Genes Dev, 2012, 26（7）：651-656.
[21] Hu S, Yu LL, Li ZM, et al. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo[J] . Cancer Biology & Therapy, 2010, 10（8）：788-795.
[22] Mallen-St Clair J, Soydaner-Azeloglu R, Lee KE, et al. EZH2 couples pancreatic regeneration to neoplastic progression[J] . Genes Dev, 2012, 26（5）：439-444.
[23] Au SLK, Wong CCL, Lee JMF, et al. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis[J] . Hepatology, 2012, 56（2）：622-631.
[24] Cai MY, Hou JH, Rao HL, et al. High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients[J] . Mol Med, 2011, 17（1-2）：12-20.
[25] Fussbroich B, Wagener N, Macher-Goeppinger S, et al. EZH2 depletion blocks the proliferation of colon cancer cells[J] . PLoS One, 2011, 6（7）：e21651.
[26] Qi W, Chan H, Teng L, et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation[J] . Proc Natl Acad Sci USA, 2012, 109（52）：21360-21365.
[27] Chase A, Cross NCP. Aberrations of EZH2 in cancer[J] . Clin Cancer Res, 2011, 17（9）：2613-2618.